Vulvovaginal atrophy in the CRETA study: the healthcare professionals’ perception

Figures & data

Table 1. Demographic features of the gynecologists and data regarding patient management.

Demographic features of gynecologists
Age (years), mean ± SD	47.2 ± 8.9
Female (%)	75.0
Years as practitioners, mean ± SD	20.8 ± 9.4
Data regarding patient management
VVA diagnosed patients seen per month (n), mean ± SD	65.5 ± 53.6
Follow-ups per year for each VVA patient (%)
1 time a year	36.4
2 times a year	43.2
3 times a year	15.9
4 or more times a year	4.5
Proportion of patients according to VVA severity (%), mean ± SD
Mild	40.7 ± 17.8
Moderate	37.3 ± 11.8
Severe	22.0 ± 13.2

SD, standard deviation; VVA, vulvovaginal atrophy.

Figure 1. Gynecologist perception regarding: (A) percentage of most frequently used therapeutic options for the treatment of VVA amongst their patients diagnosed with VVA; and (B) treatment efficacy in reversing VVA histological changes. LET, local estrogen therapy; osp, ospemifene; VM, vaginal moisturizers.

Table 2. Gynecologists’ opinion about VVA patients’ perception regarding the efficacy and safety of the different therapeutic options. Data are expressed as percentage of practitioners who selected each option (n = 44).

	VM	LET	Osp
Treatment rejection (%)	47.7	72.7	54.5
Fastest improvement treatment (%)	6.8	36.4	56.8
Higher efficacy treatment (%)	0.0	27.3	72.7
Higher side effect treatment (%)	2.3	31.8	65.9

VM, vaginal moisturizers; LET, local estrogen therapy; Osp, ospemifene.

Table 3. Gynecologists’ perception about the treatment duration and adherence of the different therapeutic options.

	VM	LET	Osp
Prescription time
1–6 months (% of practitioners)	9.1	27.3	36.4
More than 6 months (% of practitioners)	90.9	72.7	63.6
Patients not starting treatment (%, mean ± SD)	27.9 ± 19.1	31.0 ± 15.8	32.3 ± 25.2
Patients dropping out (%, mean ± SD)	47.6 ± 24.7	43.3 ± 21.1	35.5 ± 24.4
Patients missing doses (%, mean ± SD)	58.0 ± 22.8	50.9 ± 25.6	23.4 ± 14.1
Time in treatment (months, mean ± SD)	5.0 ± 4.5	5.6 ± 6.5	8.4 ± 10.1
Time to improvement (months, mean ± SD)	2.8 ± 2.7	2.1 ± 2.1	2.1 ± 2.6

VM, vaginal moisturizers; LET, local estrogen therapy; Osp, ospemifene; SD, standard deviation.